Pfizer Eyes Broader Label for RSV Vaccine Abrysvo After Promising Phase III Data

Pfizer on Tuesday unveiled top-line data from its Phase III MONeT trial, showing that its respiratory syncytial virus vaccine Abrysvo could induce immune protection in adults 18 to 59 years of age.